Menarini group and radius health announce global license agreement for the development and commercialization of elacestrant

Menarini group and radius health announce global license agreement for the development and commercialization of elacestrant.radius health - will get $30 million as upfront payment & up to $320 million in additional milestones along with tiered low to mid-teen percentage royalties.radius health inc - will continue to be responsible for conduct and completion of phase 3 emerald study through nda filing.radius health inc - costs associated with phase 3 emerald study through nda filing will be reimbursed by menarini group.
RDUS Ratings Summary
RDUS Quant Ranking